 |
All news documents are in Adobe
Acrobat (PDF) format.
- Volume
8
Published: 1998
8 Pages, 161KB - Volume
9
Published: 2000
12 Pages, 142KB - Volume
10
Published: September 2001
12 Pages, 205KB - Volume
11
Published: February 2003
12 Pages,78KB - Volume
12
Published: October 2004
16 Pages, 210KB - Volume
13
Published: 2007
19 Pages, 168KB - Volume 14
- Published: 2010
- 20 Pages, 446 KB
- Pictures from
the WAA board at the Las Vegas ASA congress, May 2006.
Center: Pr Loïc Guillevin (France), President.
Pr Siami (USA), Pr Peter Ivanovitch (USA), Pr Bernd Stegmayer (Suede), Pr Annette Bussel (France).Pr Mario Figueroa (Argentina), Pr Jacques Pourrat (France), Pr Gail Rock (Canada), Pr Robert Weinstein (USA), Pr Thomas Price (USA). - Presidential address from past president Pr Loïc Guillevin (May 2004 - March 2007) during Miami WAA congress.
-
The 14th Congress of the World Apheresis Association will be held from September 13-16, 2011 in Instanbul, Turkey.
-
For Clinician Use the help of experience from a college for the treatment of rare diagnoses - Send your question and E-mail to Bernd Stegmayr (bernd.stegmayr@medicin.umu.se) and your questions will be inserted at this place and most probably you will get a respons.
-
If you want to contribute to the knowledge of TMA: Dr. Monica Mörzell is analyzing the data of the WAA registry in regard to outcome of patients with Thrombotic Micro Angiopathy (TMA) including Thrombotic Thrombocytopenic Purpura (TTP) and Haemolytic Uremic Syndrome (HUS). She presented part of thos data at the ESAO congress in Compiegne France 2009.
If you want to contribute to the knowledge of TMA by your experience, if you have treated patients with TMA, please contact Monica Mörtzell (monika.mortzell@vll.se).
- WAA-apheresis registry: Join and register your center! The registry analyses helps us in Quality assessment and improvement and Evidence Based Medicine.
This is done by further development of the WAA apheresis registry. Data are entered free of charge and a data file is returned back to the individual center at the end of each year or, upon request by the center. By being a Center that supports the registry with data you show the community that you are eager to support the safety, efficacy, development and research of the therapeutic approaches that the WAA registry offers (www.waa-registry.org).
The registry is now also containing outcome variables for several diseases. More than 20 000 procedures have been entered. The data helps to improve knowledge, safety and skill of treatments. A short report of the activities and active centers is attached.How can we compare outcome data?
Centers who – in contrast to others- do not use apheresis for the treatment of specific diseases are encouraged to enter data into the registry. Thereby the only difference is that those centers enter the same information as those who do apheresis but mark that the procedure used is – NO TREATMENT/Control- . This will be a very important group for comparison. In principle centers from the same country can be considered to have almost the same treatment resources at the hospitals. For e.g., Guillain Barree , some physician may prefer apheresis while some others may prefer immunoglobulins or just some other treatment options. - Suggestions for Post graduate and Educational programs
Attached are two programs that have been held as Post Graduate course in Sweden and another Educational Course that directs towards, physicians and allied health personal, from the WAA - ESFH and Swiss Society for Blood Transfusion Congress held in Interlaken Sept 2010– The programs may have different content depending on local use of various techniques. Safety issues and follow up data such as registry data and quality assessment issues are suggeested to be included.
- To be posted soon...
